In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Blackstone Group makes a $500mm equity investment in Stiefel

Executive Summary

The Blackstone Group has made a $500mm minority equity investment in Stiefel Laboratories, a private company that develops dermatology and wound healing therapeutics. Stiefel will issue a new class of preferred shares and will admit a representative from Blackstone to its board of directors.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Venture Financing

Related Companies